Holen Sie sich die Stockscreener-App
101.14
0.10%
-0.105
Vorhandelsmarkt:
101.02
-0.125
-0.12%
Schlusskurs vom Vortag:
$101.25
Offen:
$101.25
24-Stunden-Volumen:
8.41M
Relative Volume:
1.71
Marktkapitalisierung:
$19.19B
Einnahmen:
$2.83B
Nettoeinkommen (Verlust:
$-1.02B
KGV:
-18.36
EPS:
-5.51
Netto-Cashflow:
$194.14M
1W Leistung:
-0.30%
1M Leistung:
+45.34%
6M Leistung:
+83.33%
1J Leistung:
+57.69%
1-Tages-Spanne:
$100.98
$101.36
1-Wochen-Bereich:
$100.98
$101.54
52-Wochen-Spanne:
$38.81
$101.87
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
101.14 | 19.21B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
575.24 | 218.08B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
227.13 | 161.37B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
717.35 | 57.97B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.32 | 42.25B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
224.92 | 38.70B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Has Exact Sciences Rally of Over 50% Left Room for Further Upside? - simplywall.st
OMERS ADMINISTRATION Corp Sells 113,387 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Published on: 2025-12-04 02:35:05 - Newser
Schroder Investment Management Group Raises Stock Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Exact Sciences (NASDAQ:EXAS) Sees Large Volume IncreaseHere's Why - MarketBeat
Top 2 Health Care Stocks You May Want To Dump This Month - Benzinga
Why Exact Sciences Corporation (EXK) stock gets analyst attentionCEO Change & Momentum Based Trading Signals - Newser
Mackenzie Financial Corp Has $151.76 Million Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Stifel downgrades Exact Sciences stock rating to Hold following Abbott acquisition news - Investing.com
This Top Dividend King Just Became an Even Better Buy - The Motley Fool
UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition - Insider Monkey
Aug EndMonth: How Exact Sciences Corporation stock performs after earningsJuly 2025 Final Week & Reliable Entry Point Trade Alerts - BỘ NỘI VỤ
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Here Are Tuesday's Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - 24/7 Wall St.
Exact Sciences (EXAS): Assessing Valuation After a 56% One-Month Rally - Yahoo Finance
Roche collaboration to accelerate Freenome’s blood-based cancer screening - Mugglehead Magazine
This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - AOL.com
Exact Sciences (EXAS) Downgraded by Canaccord Genuity, PT Raised to $105 | EXAS Stock News - GuruFocus
Champlain Investment Partners LLC Has $134.44 Million Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences stock rating downgraded to Hold by TD Cowen following Abbott deal - Investing.com
Canaccord Genuity downgrades Exact Sciences stock to Hold after Abbott deal - Investing.com
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium - Business Wire
UBS raises Exact Sciences stock price target to $105 on Abbott deal - Investing.com
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Exact Sciences (EXAS) Downgraded to Hold by Benchmark Analyst | - GuruFocus
Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - MSN
Exact Sciences (EXAS) Receives Downgrade from Jefferies Amidst P - GuruFocus
Here are Monday's Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - 24/7 Wall St.
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike - ts2.tech
Jefferies downgrades Exact Sciences stock to Hold after Abbott acquisition - Investing.com
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks - Yahoo Finance
Jim Cramer on Abbott: “I Think It’s a Terrific Time to Do Some Buying” - Yahoo! Finance Canada
Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer - Insider Monkey
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences CorporationEXAS - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Nano-X Imaging (NNOX), Exact Sciences (EXAS) - The Globe and Mail
Exact Sciences Corp Executives Engage in Stock Transactions - TradingView
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
VP Orville Sells 5,000 ($375K) Of Exact Sciences Corp [EXAS] - TradingView
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits - MSN
EXASExact Sciences Corp Stock Price and Quote - Finviz
Exact Sciences likely needs to see over $100/share in takeoveranalyst - MSN
Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle - Benzinga
Exact Sciences (EXAS): Wells Fargo Downgrades Rating, Raises Pri - GuruFocus
Abbott Laboratories to acquire Exact Sciences for $23B in largest-ever diagnostics deal - The Business Journals
Exact Sciences (EXAS) Receives Downgrade from William Blair | EX - GuruFocus
Abbott Labs stock to acquire Exact Sciences for $21 billion - Investing.com
Abbott Labs stock to acquire Exact Sciences for $21 billion By Investing.com - Investing.com UK
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):